636 related articles for article (PubMed ID: 12005221)
1. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
2. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
4. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
Bidard FC; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Cottu P; Beuzeboc P; Rolland E; Mathiot C; Pierga JY
Breast Cancer Res; 2012 Feb; 14(1):R29. PubMed ID: 22330883
[TBL] [Abstract][Full Text] [Related]
5. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus.
Tsuchiya Y; Onda M; Miyashita M; Sasajima K
Med Oncol; 1999 Apr; 16(1):31-7. PubMed ID: 10382940
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
7. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
[TBL] [Abstract][Full Text] [Related]
9. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
10. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers].
Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB
Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432
[TBL] [Abstract][Full Text] [Related]
11. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer.
Rasoul-Rockenschaub S; Zielinski CC; Kubista E; Vavra N; Pospischil E; Staffen A; Czerwenka K; Aiginger P; Spona J
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1067-72. PubMed ID: 2759162
[TBL] [Abstract][Full Text] [Related]
14. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
Murray A; Clinton O; Earl H; Price M; Moore A
Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
[TBL] [Abstract][Full Text] [Related]
15. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
16. Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma.
Rodríguez de Paterna L; Arnaiz F; Estenoz J; Ortuño B; Lanzós E
Int J Biol Markers; 1995; 10(1):24-9. PubMed ID: 7629423
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
18. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
Takada M; Masuda N; Matsuura E; Kusunoki Y; Matui K; Nakagawa K; Yana T; Tuyuguchi I; Oohata I; Fukuoka M
Br J Cancer; 1995 Jan; 71(1):160-5. PubMed ID: 7529525
[TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1. A new marker in lung cancer.
Stieber P; Hasholzner U; Bodenmüller H; Nagel D; Sunder-Plassmann L; Dienemann H; Meier W; Fateh-Moghadam A
Cancer; 1993 Aug; 72(3):707-13. PubMed ID: 7687515
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
